Literature DB >> 17436343

Antidepressants in children and adolescents--changes in utilisation after safety warnings.

Angela J Dean1, Anna Hendy, Treasure McGuire.   

Abstract

BACKGROUND: Antidepressants, in particular selective serotonin reuptake inhibitors, are one of the most commonly used classes of psychotropic drug in children and adolescents. Beginning in June 2003, evidence emerged suggesting that antidepressants may increase risk of suicidal behaviour in young people. This evidence was accompanied by national and international guidelines cautioning against use of many antidepressants in young people. This study aimed to assess whether these safety warnings have impacted upon antidepressant utilisation rates.
METHOD: This study was based at a metropolitan health service incorporating children's and adult hospitals. Total service utilisation of antidepressants was extracted from pharmacy software for the period January 2002 to December 2005. Monthly utilisation rates were computed for adults and children's services as defined daily doses (DDD) per occupied bed days. Changes in utilisation over time were examined for children and adults.
RESULTS: There was a significant relationship between time and antidepressant utilisation in children and adolescents, where antidepressant use decreased over time (R = 0.474; t = -3.66; p < 0.01), and in particular, use of SSRIs (R = 0.461; t = -3.52; p < 0.01). In contrast, use of SSRIs (R = 0.587; t = 4.91; p < 0.001) and all antidepressants (R = 0.327; t = 2.35; p < 0.05) increased over time in adults.
CONCLUSIONS: National and international warnings about safety of antidepressants in children and adolescents appear to have influenced local utilisation of these medications in young people but not in adults. Further research is required to determine optimal utilisation rates. Copyright (c) 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17436343     DOI: 10.1002/pds.1396

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  9 in total

Review 1.  Impact of safety-related regulatory action on clinical practice: a systematic review.

Authors:  Sigrid Piening; Flora M Haaijer-Ruskamp; Jonie T N de Vries; Menno E van der Elst; Pieter A de Graeff; Sabine M J M Straus; Peter G M Mol
Journal:  Drug Saf       Date:  2012-05-01       Impact factor: 5.606

2.  Effectiveness of safety warnings in atypical antipsychotic drugs: an interrupted time-series analysis in Spain.

Authors:  Gabriel Sanfélix-Gimeno; Pedro Cervera-Casino; Salvador Peiró; Beatriz González López-Valcarcel; Amparo Blázquez; Teresa Barbera
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

3.  Trends in prescribing and self-poisoning in relation to UK regulatory authority warnings against use of SSRI antidepressants in under-18-year-olds.

Authors:  Helen Bergen; Keith Hawton; Elizabeth Murphy; Jayne Cooper; Navneet Kapur; Carol Stalker; Keith Waters
Journal:  Br J Clin Pharmacol       Date:  2009-10       Impact factor: 4.335

Review 4.  Antidepressant drugs and the risk of suicide in children and adolescents.

Authors:  Göran Isacsson; Charles L Rich
Journal:  Paediatr Drugs       Date:  2014-04       Impact factor: 3.022

5.  Trends in depression and antidepressant prescribing in children and adolescents: a cohort study in The Health Improvement Network (THIN).

Authors:  Linda P M M Wijlaars; Irwin Nazareth; Irene Petersen
Journal:  PLoS One       Date:  2012-03-13       Impact factor: 3.240

Review 6.  Long-term trend in pediatric antidepressant use, 1983-2007: a population-based study.

Authors:  Xiangfei Meng; Carl D'Arcy; Raymond Tempier
Journal:  Can J Psychiatry       Date:  2014-02       Impact factor: 4.356

7.  Influences on antidepressant prescribing trends in the UK: 1995-2011.

Authors:  Becky Mars; Jon Heron; David Kessler; Neil M Davies; Richard M Martin; Kyla H Thomas; David Gunnell
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2016-11-24       Impact factor: 4.328

8.  What were the impacts of the Committee on Safety of Medicines warning and publication of the NICE guidelines on trends in child and adolescent antidepressant prescribing in primary care? A population based study.

Authors:  Paul A Tiffin; Jose L Mediavilla; Helen Close; Adetayo S Kasim; Patrick Welsh; Lewis W Paton; James M Mason
Journal:  BMJ Open       Date:  2019-08-07       Impact factor: 2.692

9.  Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan.

Authors:  Tomomi Kimura; Kazuhito Shiosakai; Yasuaki Takeda; Shinji Takahashi; Masahiko Kobayashi; Motonobu Sakaguchi
Journal:  Pharmaceutics       Date:  2012-09-19       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.